Sodium intake and multiple sclerosis activity and progression in BENEFIT
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Sodium intake and multiple sclerosis activity and progression in BENEFIT. / Fitzgerald, Kathryn C; Munger, Kassandra L; Hartung, Hans-Peter; Freedman, Mark S; Montalbán, Xavier; Edan, Gilles; Wicklein, Eva-Maria; Radue, Ernst-Wilhelm; Kappos, Ludwig; Pohl, Christoph; Ascherio, Alberto; BENEFIT Study Group; Strasser-Fuchs, S; Berger, T; Vass, K; Fredriksen, J; Kesselring, J; Petkau, A J; Toyka, K V.
I: Annals of Neurology, Bind 82, Nr. 1, 2017, s. 20-29.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Sodium intake and multiple sclerosis activity and progression in BENEFIT
AU - Fitzgerald, Kathryn C
AU - Munger, Kassandra L
AU - Hartung, Hans-Peter
AU - Freedman, Mark S
AU - Montalbán, Xavier
AU - Edan, Gilles
AU - Wicklein, Eva-Maria
AU - Radue, Ernst-Wilhelm
AU - Kappos, Ludwig
AU - Pohl, Christoph
AU - Ascherio, Alberto
AU - BENEFIT Study Group
AU - Strasser-Fuchs, S
AU - Berger, T
AU - Vass, K
AU - Fredriksen, J
AU - Kesselring, J
AU - Petkau, A J
AU - Toyka, K V
N1 - © 2017 American Neurological Association.
PY - 2017
Y1 - 2017
N2 - OBJECTIVE: To assess whether a high-salt diet, as measured by urinary sodium concentration, is associated with faster conversion from clinically isolated syndrome (CIS) to multiple sclerosis (MS) and MS activity and disability.METHODS: BENEFIT was a randomized clinical trial comparing early versus delayed interferon beta-1b treatment in 465 patients with a CIS. Each patient provided a median of 14 (interquartile range = 13-16) spot urine samples throughout the 5-year follow-up. We estimated 24-hour urine sodium excretion level at each time point using the Tanaka equations, and assessed whether sodium levels estimated from the cumulative average of the repeated measures were associated with clinical (conversion to MS, Expanded Disability Status Scale [EDSS]) and magnetic resonance imaging (MRI) outcomes.RESULTS: Average 24-hour urine sodium levels were not associated with conversion to clinically definite MS over the 5-year follow-up (hazard ratio [HR] = 0.91, 95% confidence interval [CI] = 0.67-1.24 per 1g increase in estimated daily sodium intake), nor were they associated with clinical or MRI outcomes (new active lesions after 6 months: HR = 1.05, 95% CI = 0.97-1.13; relative change in T2 lesion volume: -0.11, 95% CI = -0.25 to 0.04; change in EDSS: -0.01, 95% CI = -0.09 to 0.08; relapse rate: HR = 0.78, 95% CI = 0.56-1.07). Results were similar in categorical analyses using quintiles.INTERPRETATION: Our results, based on multiple assessments of urine sodium excretion over 5 years and standardized clinical and MRI follow-up, suggest that salt intake does not influence MS disease course or activity. Ann Neurol 2017;82:20-29.
AB - OBJECTIVE: To assess whether a high-salt diet, as measured by urinary sodium concentration, is associated with faster conversion from clinically isolated syndrome (CIS) to multiple sclerosis (MS) and MS activity and disability.METHODS: BENEFIT was a randomized clinical trial comparing early versus delayed interferon beta-1b treatment in 465 patients with a CIS. Each patient provided a median of 14 (interquartile range = 13-16) spot urine samples throughout the 5-year follow-up. We estimated 24-hour urine sodium excretion level at each time point using the Tanaka equations, and assessed whether sodium levels estimated from the cumulative average of the repeated measures were associated with clinical (conversion to MS, Expanded Disability Status Scale [EDSS]) and magnetic resonance imaging (MRI) outcomes.RESULTS: Average 24-hour urine sodium levels were not associated with conversion to clinically definite MS over the 5-year follow-up (hazard ratio [HR] = 0.91, 95% confidence interval [CI] = 0.67-1.24 per 1g increase in estimated daily sodium intake), nor were they associated with clinical or MRI outcomes (new active lesions after 6 months: HR = 1.05, 95% CI = 0.97-1.13; relative change in T2 lesion volume: -0.11, 95% CI = -0.25 to 0.04; change in EDSS: -0.01, 95% CI = -0.09 to 0.08; relapse rate: HR = 0.78, 95% CI = 0.56-1.07). Results were similar in categorical analyses using quintiles.INTERPRETATION: Our results, based on multiple assessments of urine sodium excretion over 5 years and standardized clinical and MRI follow-up, suggest that salt intake does not influence MS disease course or activity. Ann Neurol 2017;82:20-29.
KW - Adult
KW - Brain/pathology
KW - Demyelinating Diseases/diagnosis
KW - Disability Evaluation
KW - Disease Progression
KW - Female
KW - Humans
KW - Interferon beta-1b/therapeutic use
KW - Magnetic Resonance Imaging
KW - Male
KW - Multiple Sclerosis/diagnosis
KW - Neuroimaging
KW - Sodium, Dietary/adverse effects
KW - Young Adult
U2 - 10.1002/ana.24965
DO - 10.1002/ana.24965
M3 - Journal article
C2 - 28556498
VL - 82
SP - 20
EP - 29
JO - Annals of Neurology
JF - Annals of Neurology
SN - 0364-5134
IS - 1
ER -
ID: 195194624